Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Beats Estimates By $0.29 EPS

Anika Therapeutics (NASDAQ:ANIK) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.02 by $0.29, FiscalAI reports. The firm had revenue of $30.62 million during the quarter, compared to analyst estimates of $28.88 million. Anika Therapeutics had a negative net margin of 29.29% and a negative return on equity of 8.80%.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Commercial channel momentum: Commercial revenue grew 22% in Q4 and 15% for 2025, driven by international OA pain products and a more than doubling of Integrity revenue to about $6 million with >2,500 procedures and growing surgeon adoption.
• OEM headwinds: OEM revenue declined 12% in Q4 and 17% for the year due to U.S. pricing pressure (J&J MedTech) and the company expects OEM to be flat to down ~5% in 2026.
• Hyalofast regulatory uncertainty: Although the final PMA module was submitted, the FDA issued a deficiency letter on CMC and clinical data — Anika is engaging with the agency but cannot assure approval timing or outcome.
• Improving profitability and cash: Q4 GAAP gross margin expanded to 63%, full-year adjusted EBITDA was $5.3M with $11.2M operating cash flow, and planned G&A and stock-compensation actions plus manufacturing gains support 2026 guidance of $114–$122.5M revenue and 5–10% adjusted EBITDA.

Anika Therapeutics Stock Performance

NASDAQ ANIK traded up $1.57 during mid-day trading on Friday, reaching $14.36. 334,032 shares of the stock were exchanged, compared to its average volume of 150,642. The company has a market capitalization of $207.07 million, a P/E ratio of -6.30 and a beta of 0.43. Anika Therapeutics has a 1 year low of $7.87 and a 1 year high of $17.74. The business’s 50 day moving average is $9.86 and its 200-day moving average is $9.52.

Analyst Upgrades and Downgrades

ANIK has been the subject of several research reports. Wall Street Zen upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Anika Therapeutics in a research note on Monday, December 29th. Finally, Barrington Research lifted their target price on Anika Therapeutics from $16.00 to $17.00 and gave the stock an “outperform” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Key Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations — non‑GAAP EPS $0.31 vs. $0.02 consensus and revenue $30.6M vs. $28.9M consensus; the beat is the primary near‑term catalyst. Zacks: ANIK Q4 Earnings Beat
• Positive Sentiment: Barrington Research raised its price target to $17 and moved to an “Outperform,” signaling analyst confidence and providing upside to the stock. Benzinga: Barrington Research Upgrade
• Positive Sentiment: Company reiterated 2026 revenue guidance (roughly $114.0M–$122.5M reported) and set an adjusted EBITDA target while highlighting commercial‑channel expansion (commercial channel +22% in Q4, +15% full year), supporting a constructive near‑term growth outlook. GlobeNewswire: Q4 & Full‑Year 2025 Results
• Positive Sentiment: Management emphasized operational streamlining and commercial expansion, and generated positive operating cash flow ($11.2M) and free cash flow ($4.4M) for 2025 — items investors often view favorably for mid‑cycle biotech/medical device firms. Seeking Alpha: 2026 Outlook & Commercial Expansion
• Neutral Sentiment: Earnings call transcript and slide materials are available for details on product cadence, margin drivers and timing of regulatory milestones — useful for investors but not an immediate price mover by itself. SA: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reported short‑interest data in recent feeds appears to be erroneous (shows zero shares / NaN changes); no clear short‑squeeze signal from the published data. MarketBeat: ANIK Data
• Negative Sentiment: Regulatory risk: the FDA sent a response on the Hyalofast® PMA in January and Anika is preparing responses — this implies additional work/possible delays before approval and commercialization. GlobeNewswire: Regulatory Update
• Negative Sentiment: Company still reports negative net margin and negative return on equity; some analysts project a negative full‑year EPS — these fundamentals limit valuation support until profitability trends improve. MarketBeat: Earnings Summary

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Anika Therapeutics in the third quarter valued at approximately $71,000. Ieq Capital LLC purchased a new stake in Anika Therapeutics in the 4th quarter valued at $97,000. Occudo Quantitative Strategies LP purchased a new stake in Anika Therapeutics in the 3rd quarter valued at $95,000. AQR Capital Management LLC acquired a new stake in shares of Anika Therapeutics in the 1st quarter worth $181,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Anika Therapeutics during the 4th quarter worth $122,000. 91.53% of the stock is owned by hedge funds and other institutional investors.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.